Project Grant T32HL182705
Award Date 8/1/26
Completion Date 7/31/31
Dollars Obligated $438K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Chicago, IL 60611, USA
Similar Awards
- The National Institutes of Health National Heart Lung and Blood Institute awarded Ann & Robert H Lurie Children's Hospital of Chicago $876,614 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct a multisite prospective cohort study advancing acute respiratory infection treatment in pediatric invasive home mechanical ventilation. The research will enroll 400 children in English and Spanish language families using long-term home mechanical...
- The National Institutes of Health National Heart Lung and Blood Institute awarded Ann & Robert H Lurie Children's Hospital of Chicago $781,860 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the novel role of neutrophils in mediating endothelial regeneration and vascular repair in sepsis and acute respiratory distress syndrome (ARDS). The research addresses ARDS pathology, specifically endothelial barrier injury and increased vascular...
- The National Heart, Lung, and Blood Institute awarded Ann & Robert H Lurie Children's Hospital of Chicago $778,202 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to fund research targeting inflammaging-induced endothelial injury and acute respiratory distress syndrome (ARDS) development in aging lungs. The research investigates how aging influences endothelial barrier injury mechanisms in ARDS, with focus on endothelial NADPH oxidase 2 (NOX2)...
- The National Heart, Lung, and Blood Institute awarded Ann & Robert H Lurie Children's Hospital of Chicago $509,622 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to evaluate novel ultrasound techniques for assessing right ventricular diastolic dysfunction in children with pulmonary arterial hypertension. The project conducts a prospective two-center observational cohort study combining conventional ultrasound and ultrafast ultrasound (UFUS) imaging...
- The National Heart, Lung, and Blood Institute awarded Children's Research Institute $1,818,088 on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate how postnatal hypoxemia—reduced blood oxygen levels present in cyanotic congenital heart disease—impacts cardiac maturation and surgical recovery outcomes in pediatric patients. The project will examine the interaction between hypoxemia, myocardial immaturity, and postoperative complications through...
- The National Heart, Lung, and Blood Institute awarded The University of Chicago $817,976 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop single molecule footprinting methods for studying gene regulation in cardiac differentiation and disease. The recipient will combine methyltransferase-based chromatin measurement with native long-read sequencing to assess chromatin accessibility, nucleosome positioning, transcription factor binding, and DNA...
- The National Heart, Lung, and Blood Institute awarded Seattle Children's Hospital $930,637 under the Cardiovascular Diseases Research program (CFDA 93.837) on September 1, 2026, to conduct PROSPER (Pulmonary Recovery and Outcomes After Severe Pediatric Respiratory Illness), a multicenter prospective longitudinal cohort study examining how impaired pulmonary function contributes to physical and health-related quality-of-life morbidity among children surviving acute respiratory failure. The...
- The National Heart, Lung, and Blood Institute awarded Children's Research Institute $126,518 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to build a patient-oriented research mentoring program in human neonatal and infant airway biology. The award funds mentoring and research addressing mechanisms regulating airway epithelial immune responses in early life, with particular focus on populations historically excluded from respiratory research: infants with...
- The National Institutes of Health National Heart, Lung, and Blood Institute awarded The Children's Hospital of Philadelphia $1,741,543 on September 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate lung injury in pediatric hematopoietic cell transplant recipients. The research examines molecular mechanisms of pulmonary toxicity in pediatric HCT recipients, who experience lung injury in up to 40% of cases with mortality rates of 40% when requiring...
- The National Heart, Lung, and Blood Institute awarded The Children's Hospital of Philadelphia $115,584 on July 3, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to support computational and experimental investigations of deformation-driven molecular pathways in single right ventricle congenital heart disease. The project, a K25 career development award, will fund research into tricuspid valve regurgitation in pediatric patients with single right ventricle congenital heart...